产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 97% | 询价 | |||
| 5mg | 97% | 询价 | |||
| 10mg | 97% | 询价 | |||
| 25mg | 97% | 询价 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 97% | 询价 | |||
| 5mg | 97% | 询价 | |||
| 10mg | 97% | 询价 | |||
| 25mg | 97% | 询价 |
CAS No. |
258818-34-7 |
|---|---|
中文名称 |
2-((S)-1-((2S,5S,8S,11S)-17-氨基-2-(3-氨基-3-氧代丙基)-8-异丁基-5,11-二异丙基-4,7,10,13,16-五氧代-3,6,9,12,15-五氮杂十七烷-1-酰基)吡咯烷-2-甲酰氨基)乙酸 |
英文名称 |
2-((S)-1-((2S,5S,8S,11S)-17-Amino-2-(3-amino-3-oxopropyl)-8-isobutyl-5,11-diisopropyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaheptadecan-1-oyl)pyrrolidine-2-carboxamido)acetic acid |
别名 |
Unii-zn3R5560zv;larazotide;Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine;Gly-Gly-Val-Leu-Val-Gln-Pro-Gly;Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-;AT 2347;AT2347;AT-2347 |
标准英文名 |
glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine |
分子式 |
C32H55N9O10 |
分子量 |
725.84 |
精确分子量 |
725.41 |
SMILES |
O=C(O)CNC([C@H]1N(C([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC(CNC(CN)=O)=O)=O)=O)=O)=O)CCC1)=O |
标准SMILES |
CC(C)[C@H](NC(=O)CNC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O |
用途 |
Larazotide is an inhibitor peptide composed of an 8-amino acid sequence and is the primary active ingredient of the only drug candidate currently in Phase III clinical trials specifically developed for the treatment of celiac disease. In the body, larazotide helps normalize tight junctions in the intestinal epithelial cells of celiac patients, preventing the entry of gluten-derived gliadin peptides into systemic circulation and thereby inhibiting the associated inflammatory response. |
InChIKey |
ORFLZNAGUTZRLQ-ZMBVWFSWSA-N |
|
|
评论 |
|---|